Cyclacel Reports Phase 2 Survival Data With Sapacitabine in Myelodysplastic Syndromes at 2010 ASH … – Yahoo Finance

Posted on December 16, 2010 by admin

BERKELEY HEIGHTS, N.J., Dec. 4, 2010 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC – News ) (Nasdaq: CYCCP – News ) (“Cyclacel”) announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel … Bing News – Full Story →

Share

Related posts:

  1. Promising Data on Amgen Drug – Yahoo Finance
  2. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohn’s Disease to be … – Yahoo Finance
  3. Cytokinetics, Incorporated Reports Third Quarter 2010 Financial Results – msnbc.com
  4. Idera Pharma (IDRA) To Present Data for TLR 7 and TLR 9 on Hyperlipidemia – StreetInsider.com
  5. XenoPort Reports Third Quarter Financial Results – Yahoo Finance
This entry was posted in Myelodysplastic Syndromes and tagged , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>